Bayer's Sevabertinib Wins First-Line HER2-Mutant NSCLC Approval

The FDA granted accelerated approval on September 9 to Bayer’s sevabertinib (Hyrnuo), an oral HER2 tyrosine kinase inhibitor, for adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors carry HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations. The decision expands the accelerated approval sevabertinib won in November 2025 for patients who had already received systemic therapy, moving the drug into the treatment-naive setting where no HER2-targeted therapy was previously available.

The approval rests on SOHO-01 (NCT05099172), an ongoing Phase I/II trial. Among 69 treatment-naive patients, sevabertinib produced a confirmed objective response rate (ORR) of 75% (95% CI: 64-85), with 73% of responders holding a response for at least six months and 38% for at least 12 months. The recommended dose is 20 mg orally twice daily with food. The label carries warnings for diarrhea, hepatotoxicity, interstitial lung disease and pneumonitis, left ventricular dysfunction, ocular toxicity, and embryo-fetal toxicity.

The approval makes sevabertinib the first HER2-directed therapy to win an FDA label in the first-line HER2-mutant NSCLC setting. It beats AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), which reported a positive DESTINY-Lung04 Phase 3 readout in August but remains approved only for previously treated patients. See our coverage of the DESTINY-Lung04 readout.

The front-line label is the larger commercial prize. Activating HER2 mutations appear in 2% to 4% of advanced NSCLC, often in younger patients who have never smoked, and the mutation is tied to poor prognosis. Moving sevabertinib earlier expands its addressable population and gives it a head start ahead of Enhertu’s own first-line push, which still needs a confirmatory overall survival readout and a regulatory decision.

The review was conducted under Project Orbis with the UK’s MHRA, and sevabertinib carried Priority Review, Breakthrough Therapy, and Orphan Drug designations. Because the approval is accelerated, Bayer must confirm clinical benefit in a follow-up trial, with response durability standing in as the surrogate endpoint for now.

Bayer’s ADR (BAYRY) closed at $14.31 on September 9, essentially flat. Bayer is a diversified pharma and crop-science company, so a niche oncology label expansion barely moves the stock even when it carries first-line significance.

What to watch next: sevabertinib’s confirmatory trial data, and the DESTINY-Lung04 overall survival readout, which will determine whether Enhertu can challenge sevabertinib for the first-line position.

What It Means for the Trade

The trade to have was Bayer-adjacent exposure before the label expansion, not after — and even then, BAYRY barely moved, because a niche oncology label in a crop-science-heavy conglomerate is a rounding error. The flat close on approval day is the market correctly pricing this: sevabertinib will not move Bayer’s numbers for years, if ever, given the size of the HER2-mutant NSCLC population (2-4% of advanced NSCLC). For traders, the significance is field-level, not stock-level.

The field-level point: sevabertinib just moved the goalposts for Enhertu in lung cancer. Daiichi Sankyo and AstraZeneca have marketed Enhertu’s NSCLC franchise on the strength of DESTINY-Lung01/02 response rates in the pretreated setting, and DESTINY-Lung04 was their first-line entry ticket. Sevabertinib now owns that position with an accelerated label, months of launch runway, and an oral dosing advantage over an IV ADC. Enhertu’s response to that will be an OS-based counter-argument: DESTINY-Lung04’s confirmatory OS readout is the asset’s best shot at reclaiming the first-line narrative, because an oral TKI with 75% ORR in a single-arm cohort has not demonstrated a survival benefit and cannot until its own confirmatory trial reports. The battle is now “durable responses, convenient pill, accelerated label” versus “OS data, IV burden, full label pending.” Oncologists split on that trade-off; payers and patients lean toward the pill.

Mechanism and Market Context

Mechanistically, sevabertinib and Enhertu attack the same target from different directions. Sevabertinib is an oral TKI that binds the HER2 tyrosine kinase domain — the same mutant receptor population that drives the disease — while Enhertu is an antibody-drug conjugate that carries a topoisomerase-I payload to HER2-expressing cells regardless of kinase activity. That distinction matters for patient selection: TKD-activating mutations are sevabertinib’s label territory, and the TKI class has historically struggled against HER2 amplification or non-mutant overexpression, where ADCs shine. The label’s TKD-mutation restriction is precise, and that precision is both a strength (clean target population, 75% ORR) and a ceiling (a subset of a 2-4% subset).

The safety profile is where the two drugs really diverge. Sevabertinib’s label carries warnings for diarrhea, hepatotoxicity, interstitial lung disease/pneumonitis, left ventricular dysfunction, and ocular toxicity — a heavy list for an oral TKI, and ILD/pneumonitis is the warning that grabs oncologists because it is the same boxed-risk class issue that haunts HER2-directed therapy generally. Enhertu’s own well-documented ILD risk means neither drug wins on safety; the differentiator is that sevabertinib’s ILD signal is a warning rather than a boxed one, and dosing is at home rather than an infusion chair. In a population skewing younger and never-smoker, convenience is not trivial — these are often patients who want to keep working.

Risks and What Could Go Wrong

1. Accelerated approval is conditional credit: if the confirmatory trial disappoints, the FDA has shown no hesitation in withdrawing oncology accelerated approvals. The entire first-line label could unwind.
2. DESTINY-Lung04’s OS readout could be decisive, giving Enhertu a survival label that a response-rate-based TKI filing cannot match, and oncology practice moves on OS.
3. The SOHO-01 ORR of 75% is from a Phase I/II single-arm cohort, not a randomized comparison against standard first-line chemo — no placebo arm, no head-to-head with Enhertu. Cross-trial comparisons of ORR between SOHO-01 and DESTINY cohorts are not evidence; only the confirmatory randomized data will be.
4. Label-restricted usage: if TKD testing adoption lags, or if oncologists treat HER2-mutant lung cancer off-label with Enhertu first anyway, the front-line head start evaporates regardless of what the label says.

For Bayer holders this changes nothing about the investment case — the crop-science turnaround and pipeline litigation matter more. For the trade, the actionable version of this story is watching when DESTINY-Lung04’s OS data lands and how Daiichi Sankyo/AstraZeneca respond on the first-line filing. That is a catalyst on their calendars, not Bayer’s.

Source: FDA announcement; Bayer press release; SOHO-01 on ClinicalTrials.gov (NCT05099172).